Skin and Joints Podcast

🇨🇦🇺🇸 Cross-Border Talk: High Fives, Higher Standards — Rethinking the Treatment Finish Line (Part 2 of 2)🎰 What happens in Vegas doesn't always stay in Vegas—especially when it could change how we treat patients! 🇨🇦 Team Canada and 🇺🇸 Team USA are back for Round 2!Live from Fall Clinical 2026 in Las Vegas, Canadian dermatologist Dr. Andrei Metelitsa and American dermatologist Dr. Christopher Bunick return to the Skin and Joints Podcast for Part 2 of our Cross-Border Talk series.This time we're raising the stakes—and the standard of care.🤔 What good is a better eczema score if your patient still can't sleep, work, or even shake someone's hand?Our experts go beyond skin clearance to explore why minimal disease activity, patient-reported outcomes, and real-world functionality should be central to how we define treatment success in atopic dermatitis and chronic hand eczema.🔬 Diving deeper into the AD Hand study, they unpack emerging tralokinumab data showing meaningful improvements in quality of life and hand function. But how quickly should patients expect results? And when is an improving partial response good enough—or a signal to rethink the treatment plan?🩺 Then comes the ultimate cross-border real world clinical challenge: a 38 year old nurse whose painful hand eczema threatens her ability to work, despite optimized topical therapy. Would Team Canada and Team USA approach treatment differently? When is it time to escalate therapy—and what happens once patients finally achieve clear skin?💡 From biologics and JAK inhibitors to shared decision-making, irritant avoidance, and the intriguing question of what happens after patients achieve clear skin, this conversation serves up practical clinical pearls—with a few laughs along the way.🙌 Two countries. One treatment goal. Helping patients high-five with confidence again! 🎯 Learning ObjectivesFollowing this episode, healthcare professionals should be able to:Redefine meaningful treatment success: Discuss the clinical value of minimal disease activity and more stringent treat-to-target goals, integrating skin clearance, itch control, and patient-reported outcomes rather than relying solely on conventional disease severity scores.Translate clinical trial findings into real-world outcomes: Interpret findings from the AD Hand study examining tralokinumab's impact on Dermatology Life Quality Index (DLQI) and Hand Eczema Impact Scale (HEIS) outcomes, and consider their relevance to daily functioning and quality of life.Set realistic treatment expectations: Evaluate the significance of early responses, continued improvement over time, and partial treatment responses when counselling patients with atopic hand eczema, while recognizing the importance of ongoing skin care and irritant avoidance.Navigate treatment escalation in high-burden disease: Apply a patient-centred approach to clinical decision-making in patients with functionally debilitating atopic hand eczema, including consideration of biologics, JAK inhibitors, occupational factors, concomitant therapies, and differences in treatment availability across Canada and the United States.Look beyond achieving clear skin: Explore emerging considerations for long-term disease control, maintenance strategies, dosing flexibility, and potential treatment de-escalation once patients achieve meaningful disease control, while recognizing the limits of current evidence. 🎲 The stakes are high, the clinical pearls are plenty, and the borders are open for debate.Because at the end of the day, successful eczema treatment isn't just about how the skin looks—it's about what patients can finally get back to doing. 🙌#SkinAndJoints #CrossBorderTalk #FallClinical2026 #AtopicDermatitis #ChronicHandEczema #ADHand #JAKs #MinimalDiseaseActivity #PatientReportedOutcomes #Dermatology #TreatToTarget  SUPPORTED BY AN IME GRANT FROM LEO Pharma.  About Dr. Christopher Bunick MD, PhD.Dermatologist  |  New Haven, CT, USA BIOGRAPHYDr. Christopher Bunick is an Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine. Clinically, he specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. Dr. Bunick received his B.S. at Vanderbilt University (Nashville, TN), and his M.D. and Ph.D. degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g. the skin disease xeroderma pigmentosum). He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at the Yale University School of Medicine (New Haven, CT). He performs lab research with the goal of better understanding the structure-function relationship of proteins involved in normal and diseased skin and dermatologic therapeutics. His work emphasizes translation of biochemical and structural research findings into clinically meaningful and practice-changing discoveries. His work to date has advanced the field’s understanding of: (i) the molecular mechanisms of the human skin barrier; (ii) assembly mechanisms of intermediate filaments, like keratin and vimentin, leading to patents for new cytoskeleton-targeted therapeutics; (iii) the biochemical basis for antibiotic activity and resistance in Cutibacterium acnes and acne vulgaris; (iv) the structure-function relationships of anti-IL23 psoriasis biologics and how that impacts clinical efficacy; (v) the structure-function relationships of multiple dermatologic therapeutics, including atopic dermatitis biologics, Janus kinase inhibitors, PDE4 inhibitors, and more. Chris’ research has pioneered a new focus in dermatology on fundamental biochemistry and structural biology, particularly around connecting the atomic resolution mechanisms of action of a therapeutic to its clinical performance and safety. Complementing his basic science research, Chris has and continues to lead multiple dermatology clinical trials at the Yale Center for Clinical Investigation. About Dr. Andrei Meteitsa MD, FRCPC, FAAD.Dermatologist  |  Calgary, ABAndrei Metelitsa, MD, FRCPC is a board-certified dermatologist in both Canada and United States. He is Co-Director of the Institute for Skin Advancement in Calgary, Alberta and serves as a Clinical Associate Professor at the University of Calgary. He completed his dermatology training at the University of Alberta, followed by 1 year fellowship training in Lasers and Cosmetic Surgery with SkinCare Physicians in Boston, under the direction of world-renowned faculty from Harvard University and Yale University.Dr. Metelitsa is an author of a dermatology book, as well as more than 40 book chapters and articles. His major cosmetic interests include laser surgery, non-surgical fat reduction and facial rejuvenation. He is also an avid skin cancer researcher, with a particular interest on epidemiology in Canada. Dr. Metelitsa has received more than 35 academic, research, leadership and volunteer awards throughout his career. 📻www.skinandjoints.ca✉️[email protected]

🎰 Cross-Border Talk: High Stakes, Higher Standards — Rethinking Atopic Dermatitis & Chronic Hand Eczema (Part 1 of 2)🇨🇦 Team Canada vs. Team USA. Different borders, shared clinical challenges—and a few (somewhat friendly) disagreements along the way!🎙️ Live from Fall Clinical 2026 in Las Vegas, the Skin and Joints Podcast brings back its popular Cross-Border Talk segment, featuring Canadian dermatologist Dr. Andrei Metelitsa and American dermatologist Dr. Christopher Bunick.From exchange-rate banter to exchanging clinical pearls, the conversation quickly turns to some big questions in dermatology: Are we intervening early enough? Have we become too comfortable with corticosteroids? And are we setting the bar high enough for treatment success?🔥 In Part 1 of this two-part conversation, our experts unpack their biggest takeaways from Fall Clinical, challenge conventional thinking around JAK inhibitor safety, and explore why corticosteroid stewardship and newer non-steroidal therapies could help break the cycle of therapeutic inertia in chronic hand eczema.🔬 The discussion gets beneath the surface—literally—as they examine emerging pediatric TRAPEZE-1 data exploring IL-13 inhibition and skin barrier biomarkers, alongside AD Hand study findings that challenge how we define disease severity and meaningful treatment outcomes.💡 And perhaps the biggest question: If a patient has limited skin involvement but can't sleep, work, or function because of their eczema, can we really call their disease mild?Two countries. Two dermatologists. One candid conversation about raising the standard of care.Because when it comes to better dermatology care, some boundaries are worth crossing. 🌎🎯 Learning ObjectivesAfter listening to this episode, healthcare professionals should be able to:Rethink early intervention: Discuss the clinical rationale for earlier use of advanced therapies in inflammatory skin diseases and evaluate evolving evidence surrounding JAK inhibitor safety in atopic dermatitis.Challenge the corticosteroid status quo: Recognize therapeutic inertia in chronic hand eczema and explore how steroid stewardship, non-steroidal topical therapies, and appropriate treatment escalation can improve long-term management.Look beyond visible skin clearance: Interpret exploratory TRAPEZE-1 pediatric findings on skin barrier biomarkers following IL-13 inhibition, while distinguishing potential barrier restoration from established disease modification.Redefine disease burden: Examine how atopic hand eczema can profoundly affect itch, pain, sleep, daily functioning, and quality of life despite relatively limited body surface area involvement.Raise the treatment bar: Discuss minimal disease activity and the value of integrating clinician-assessed outcomes with patient-reported outcomes when establishing meaningful treatment goals.🇨🇦 🇺🇸 Two perspectives. Plenty of clinical pearls. No passport required.#SkinAndJoints #CrossBorderTalk #FallClinical2026 #AtopicDermatitis #ChronicHandEczema #SteroidStewardship #SkinBarrier #JAKInhibitors #Dermatology SUPPORTED BY AN IME GRANT FROM LEO Pharma.  About Dr. Christopher Bunick MD, PhD.Dermatologist  |  New Haven, CT, USA BIOGRAPHYDr. Christopher Bunick is an Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine. Clinically, he specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. Dr. Bunick received his B.S. at Vanderbilt University (Nashville, TN), and his M.D. and Ph.D. degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g. the skin disease xeroderma pigmentosum). He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at the Yale University School of Medicine (New Haven, CT). He performs lab research with the goal of better understanding the structure-function relationship of proteins involved in normal and diseased skin and dermatologic therapeutics. His work emphasizes translation of biochemical and structural research findings into clinically meaningful and practice-changing discoveries. His work to date has advanced the field’s understanding of: (i) the molecular mechanisms of the human skin barrier; (ii) assembly mechanisms of intermediate filaments, like keratin and vimentin, leading to patents for new cytoskeleton-targeted therapeutics; (iii) the biochemical basis for antibiotic activity and resistance in Cutibacterium acnes and acne vulgaris; (iv) the structure-function relationships of anti-IL23 psoriasis biologics and how that impacts clinical efficacy; (v) the structure-function relationships of multiple dermatologic therapeutics, including atopic dermatitis biologics, Janus kinase inhibitors, PDE4 inhibitors, and more. Chris’ research has pioneered a new focus in dermatology on fundamental biochemistry and structural biology, particularly around connecting the atomic resolution mechanisms of action of a therapeutic to its clinical performance and safety. Complementing his basic science research, Chris has and continues to lead multiple dermatology clinical trials at the Yale Center for Clinical Investigation. About Dr. Andrei Meteitsa MD, FRCPC, FAAD.Dermatologist  |  Calgary, ABAndrei Metelitsa, MD, FRCPC is a board-certified dermatologist in both Canada and United States. He is Co-Director of the Institute for Skin Advancement in Calgary, Alberta and serves as a Clinical Associate Professor at the University of Calgary. He completed his dermatology training at the University of Alberta, followed by 1 year fellowship training in Lasers and Cosmetic Surgery with SkinCare Physicians in Boston, under the direction of world-renowned faculty from Harvard University and Yale University.Dr. Metelitsa is an author of a dermatology book, as well as more than 40 book chapters and articles. His major cosmetic interests include laser surgery, non-surgical fat reduction and facial rejuvenation. He is also an avid skin cancer researcher, with a particular interest on epidemiology in Canada. Dr. Metelitsa has received more than 35 academic, research, leadership and volunteer awards throughout his career. 📻www.skinandjoints.ca✉️[email protected]

 Part 3 of 3: Our Practical Playbook When Skin & Gut Don’t Read the Same Treatment PlanWhat happens when the skin is crystal clear…but the Crohn’s disease didn’t get the memo? 👀In the final chapter of our special Derm × GI crossover conversation, our Faculty Dr. Perry Grewal and Dr. Jesse Siffledeen get practical about what happens after the prescription is written.From treat-to-target monitoring and follow-up cadence to the very real influence of insurance requirements, our experts unpack how they decide whether a therapy is truly working—and what to do when different organ systems are telling very different stories.🧩 Great skin, active gut?🧩 Controlled IBD, stubborn psoriasis?🧩 One therapy, two diseases…or occasionally two therapies?The conversation explores how clinicians prioritize competing treatment targets without sacrificing what matters most to the patient, why success may need to be measured beyond a single organ system, and where communication between specialties becomes essential.And perhaps the simplest clinical pearl of the entire series? Ask the questions—and don’t be afraid to pick up the phone.Because when inflammatory disease crosses specialties, the best care probably should too. 🎯 Learning ObjectivesAfter listening to this episode, participants should be able to:Describe practical approaches to monitoring treatment response across dermatologic and gastrointestinal inflammatory diseases, including the role of early clinical follow-up and objective assessment.Evaluate therapeutic options when disease control differs across organ systems, such as controlled psoriasis with active IBD or controlled IBD with persistent skin disease.Discuss the limitations of organ-specific treatment targets and incorporate patient priorities, disease severity, and multisystem outcomes when defining therapeutic success.Recognize how payer and insurance requirements can influence treatment selection, reassessment schedules, access, and consideration of dual therapy.Identify key questions that dermatology and gastroenterology clinicians can ask to recognize disease manifestations outside their own specialty and facilitate timely referral.Apply practical strategies for multidisciplinary co-management, including direct clinician-to-clinician communication and collaborative treatment decision-making,🔥 In This Episode🔬 Treat-to-target: when should you actually reassess?🎯 One patient, two organs: does success require both to be at target?🔄 Great skin, active gut—or vice versa: when do you switch?💊 Dual therapy: useful tool or access nightmare?💰 When insurance starts influencing the clinical calendar🗣️ Why asking about the gut–skin–joint connection matters📞 The underrated power of simply calling your colleague🤝 Why multidisciplinary care needs to move from concept to everyday workflow  #SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #TreatToTarget #Biologics #IL23 #InflammatoryDisease #MultidisciplinaryCare #PrecisionMedicine #PatientCentredCare #MedicalEducation #HCPeducation  SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson. ABOUT Dr. Parbeer GrewalDermatologist, Edmonton, ABDr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology. Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology. He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services. ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, ABDr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium.Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011.  📻www.skinandjoints.ca✉️[email protected]

🎙️ Beyond Skin Deep & Gut Feelings — Part 2: When the Gut and Skin Share the Treatment PlanOne patient. Two organ systems. And suddenly, choosing a biologic gets a whole lot more interesting. 👀In Part 2 of our Derm × GI crossover, podcast Faculty members dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen move from diagnosis into the real-world treatment decisions that happen when psoriasis and inflammatory bowel disease collide.PRO-TIPS COVERED: How do you practically choose one therapy when you’re treating two inflammatory diseases? When might suspected IBD steer a dermatologist away from an IL-17 inhibitor? What happens when the dose needed for Crohn’s disease doesn’t match the dose used for psoriasis? And when one drug isn’t enough, is dual advanced therapy the next frontier—or an insurance headache waiting to happen? 😅The conversation also digs into the very different therapeutic ceilings in dermatology and gastroenterology, including emerging data in perianal Crohn’s disease, the challenge of achieving true mucosal healing, and why GI may still be chasing remission rates that dermatology has already learned to expect from modern psoriasis therapy.It gets practical: Who owns the prescription? Who takes the lead when one organ system flares? How much communication is really needed between specialists? And where do vaccinations fit when advanced therapy needs to start quickly?From IL-23s vs IL-17s to biologic dosing, multidisciplinary care, vaccine timing and the occasional therapeutic turf war, this is where “shared care” leaves the PowerPoint slide and enters actual clinical practice. 🧩🎯 Learning ObjectivesAfter listening to this episode, participants should be able to:Compare key clinical factors that influence advanced therapy selection in patients with psoriasis and coexisting or suspected inflammatory bowel disease.Explain how IL-17, IL-23 and TNF-targeted therapies may be approached differently when Crohn’s disease, fistulizing disease or possible IBD is part of the clinical picture.Discuss real-world challenges in multidisciplinary treatment, including differing doses across indications, prescription ownership, reimbursement barriers and situations where dual advanced therapy may be considered.Contrast treatment targets in psoriasis and IBD, including PASI-based skin clearance versus clinical remission, endoscopic improvement and mucosal healing.Identify practical approaches to vaccination and treatment onboarding for patients starting biologic or other advanced systemic therapies.🎧 Part 2 of 3 — stay tuned for Part 3 as the conversation moves into monitoring and treat-to-target across the skin–gut axis.#SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #Biologics #IL23 #IL17 #TNFInhibitors #InflammatoryDisease #PrecisionMedicine #MultidisciplinaryCare #MedicalEducation #HCPeducation 🧬🩺💊 SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson. ABOUT Dr. Parbeer GrewalDermatologist, Edmonton, ABDr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology. Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology. He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services. ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, ABDr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium.Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011. 📻www.skinandjoints.ca✉️[email protected] 📻www.skinandjoints.ca✉️[email protected]

Not every loose stool is Crohn’s. Not every rash is “just a rash.” And sometimes the most useful clinical tool is knowing exactly which colleague to text.In Part 1 of our special Skin and Joints Podcast crossover, we go beyond skin deep and gut feelings with dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen to tackle what Derm–GI collaboration actually looks like, or could look like in the real world.Psoriasis and inflammatory bowel disease may live in different specialty clinics, but for many patients, the boundaries aren’t nearly so tidy.What should make a dermatologist start thinking about the gut? Which GI symptoms deserve a routine referral—and which ones should make your clinical “spidey sense” start tingling?Our guest experts get practical about:🔎 The GI red flags worth screening for in patients with psoriatic disease🚨 When a referral can wait—and when it probably shouldn’t🧪 Where fecal calprotectin, inflammatory markers and anemia fit into the picture📲 Why sometimes a colleague’s name, and a quick message can be more useful than an elaborate referral pathway📝 What actually needs to go into a useful Derm-to-GI or GI-to-Derm referral🧩 How to begin separating IBD from common mimics such as IBS and post-infectious symptoms💊 Why recognizing coexisting immune-mediated disease can influence treatment decisionsAnd perhaps most importantly: multidisciplinary care doesn’t always require a multidisciplinary clinic.🎯 Learning ObjectivesBy the end of Part 1, listeners should be able to:Recognize key gastrointestinal signs, symptoms and clinical red flags that may warrant further investigation for IBD in a patient presenting with psoriatic disease.Differentiate between routine, urgent and potentially emergent GI referral scenarios based on symptoms, systemic illness and available objective findings.Describe practical strategies for Derm–GI co-management, including effective communication and the essential information to include when referring between specialties.Explain how suspected or confirmed gastrointestinal comorbidity may influence therapeutic decision-making in patients with immune-mediated disease.Identify clinical features that can help distinguish IBD from common gastrointestinal mimics, while recognizing when specialist assessment is warranted.🎧 Two specialties. One patient. And a lot more overlap than the clinic schedule might suggest.#SkinAndJointsPodcast #Dermatology #Gastroenterology #Psoriasis #IBD #CrohnsDisease #UlcerativeColitis #ImmuneMediatedDisease #MultidisciplinaryCare #MedicalEducation #DermGI #ClinicalPracticeSUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson. ABOUT Dr. Parbeer GrewalDermatologist, Edmonton, ABDr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology. Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology. He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services. ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, ABDr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium.Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011. 📻www.skinandjoints.ca✉️[email protected]   📻www.skinandjoints.ca✉️[email protected]

🎙️ HS & Biosimilars: The Switch Pitch — Part 3 Final drop, biggest pearls. 💎 Is HS is the new acne? How can we treat early, treat seriously, and help prevent long-term scarring—physical and emotional? In Part 3 of our real-world HS conversation, Skin and Joints Podcast F aculty Dr. Lauren Lam and Dr. Marni Wiseman bring the discussion home with practical, clinic-ready insights for dermatologists navigating biosimilars, biologics, comorbidities, obesity, smoking, PSP realities, and the art of building trust over time. From why GLP-1s are not a substitute for HS-directed biologic therapy, to how to incorporate non-stigmatizing conversations around obesity and smoking cessation in the clinic, this episode gets into the real-world nuance that does not always fit neatly into an algorithm.  And when it comes to choosing between a TNF biosimilar and IL-17 options?  How dos comorbidities, contraindications, access, PSP fit, disease severity, and the patient sitting in front of you all factor in for each? Find out here. 👩‍⚕️🧠 Learning Objectives By the end of this episode, listeners will be able to: Describe practical considerations for managing HS beyond acute flares, including longitudinal disease control and early biologic initiation in appropriate patients. Discuss how GLP-1 therapies may fit as adjunctive care in select HS patients, while recognizing that they do not replace targeted HS biologic or biosimilar therapy. Apply non-stigmatizing, patient-centred approaches when discussing obesity and smoking cessation in HS care. Identify key factors that influence selection between TNF biosimilars and IL-17 therapies, including comorbid IBD, rheumatoid arthritis, contraindications, candidiasis risk, disease severity, and access. Recognize the role of PSPs, samples, dose optimization, and follow-up planning in improving real-world HS treatment continuity.   #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #Biosimilars #Biologics #InflammatorySkinDisease #MedicalEducation #DermTwitter #DermatologyEducation #PatientCentredCare #RealWorldDermatology #PSP #IL17 #TNF #ClinicalPearls 💉🧬🎙️   ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca✉️[email protected]

🎙️ PART 2:  HS & Biosimilars: The Switch Pitch — Real-World Pearls from the Clinic 💉🔥🧴 In Part 2 of our HS and biosimilars conversation, we’re getting practical — very practical. 🎧🩺 Faculty Dr. Lauren Lam and Dr. Marni Wiseman join the Skin and Joints Podcast to unpack what really matters when biosimilars move from policy, paperwork, and prescribing forms… into the real lives of patients with hidradenitis suppurativa. 📋➡️💪 From the science of biosimilarity and extrapolating evidence across inflammatory diseases, to the clinic-level details dermatologists cannot afford to overlook — injection pain, citrate-free formulations, device ergonomics, dosing convenience, patient support programs, rural drug delivery, reload strategies, and yes… whether the PSP actually calls the patient back. ☎️🚚💉 Because in HS, the best biologic or biosimilar is not just about the molecule. It is about momentum, access, trust, support, and getting treatment into the patient’s hands before they disappear from the care journey. 🧭🤝 The conversation also takes a timely turn into obesity, systemic inflammation, GLP-1/GIP therapies, and whether metabolic care may become part of the next frontier in HS management. ⚖️🔥🔬 Consider this your field guide to biosimilar switching in HS — with clinic hot tips, PSP reality checks, and a reminder that sometimes the smallest formulation detail can make the biggest difference to the person injecting every week. 💡💉🙌   Learning Objectives: By the end of this episode, listeners will be able to: Explain how biosimilar evidence may be extrapolated across inflammatory diseases and how this applies to real-world HS care. 🔬 Identify key formulation and device factors that may influence patient comfort, adherence, and treatment experience with adalimumab biosimilars. 💉 Describe the role of patient support programs (PSPs) in treatment initiation, onboarding, access, monitoring, and long-term engagement for patients with HS. 🤝 Recognize practical barriers to biosimilar use in HS, including injection training, treatment delays, rural/remote medication delivery, and patient disillusionment. 🚚 Discuss emerging considerations around obesity, systemic inflammation, and GLP-1/GIP therapies as part of the evolving HS care conversation. ⚖️🔥= #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #MedicalDermatology #Biosimilars #Adalimumab #InflammatorySkinDisease #DermatologistEducation #RealWorldDermatology #PatientSupportPrograms #Biologics #ClinicalPearls #DermatologyPodcast #HSManagement 🧴💉🔥🎧🩺   ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca✉️[email protected]

🎙️🇨🇦🇺🇸. Hands On, Gloves Off: Cross-Border Talk on Atopic Hand Eczema We’re coming to you from the heart of Music City, Nashville 🎸 — but don’t worry, this Cross-Border Talk is not about trade, tariffs, or hockey rivalries. This time, it’s all hands on deck. ✋🇨🇦🇺🇸 In this episode of the Skin and Joints Podcast from RAD 2026, our Cross-Border Dermatologist Faculty Dr. Raj Chovatiya from the U.S. joins Canadian favourite Dr. Melinda Gooderham for a lively, practical, and focused conversation on atopic hand eczema, chronic hand eczema, and fresh week 32 data exploring tralokinumab in this challenging and high-burden body site. Hands may represent a small body surface area, but they carry an outsized burden. They are exposed, functional, visible, constantly irritated, and central to work, hobbies, caregiving, gardening, handshakes, procedures, and everyday life.  In other words: when the hands are flaring, patients are not just uncomfortable — they are often functionally sidelined. 🧤🌱 This episode goes beyond the usual did the trial hit the endpoint discussion and digs into the real-world so what? You’ll hear how the week 32 data may help frame expectations, why some patients may need more time before being labelled non-responders, how itch and pain improvements matter alongside clearance, and how shared decision-making can turn clinical trial endpoints into conversations patients actually understand. 📊🩺 The discussion also gets practical on where tralokinumab may fit alongside emerging topical options like delgocitinib, how to think about atopic hand eczema versus broader chronic hand eczema phenotypes, and why a back to basics approach remains timeless advice when patients are not responding as expected. 🔍 From Nashville notes to Monday morning clinic, this Cross-Border Talk offers a hands-on look at atopic hand eczema — with just enough clinical soil turned over to leave you wanting the full episode. 🎙️✋   Learning Objectives 🎯 After listening to this episode, listeners will be able to: Describe the clinical and functional burden of atopic hand eczema✋, including why hands represent a uniquely challenging and high-impact treatment site despite limited body surface area involvement. Summarize key elements of the week 32 tralokinumab data in atopic hand eczema📊, including trial design, patient population, efficacy signals, symptom outcomes, and tolerability considerations. Interpret week 16 versus week 32 response data through a real-world clinical lens🕒, including how to counsel partial responders and avoid prematurely labelling treatment as failure. Integrate patient-reported outcomes into treatment decision-making🗣️, particularly itch, pain, function, visibility, and the patient’s ability to return to meaningful daily activities. Differentiate treatment considerations for atopic hand eczema versus broader chronic hand eczema🧩, including when topical, systemic, or combination strategies may be appropriate. Apply practical clinic-based reassessment strategies for patients with persistent hand eczema🔍, including evaluation for irritant contact dermatitis, allergic contact dermatitis, occupational exposures, and ongoing trigger management.   ABOUT Dr. Raj Chovatiya, MD, PhD, MSCI Associate Professor | Rosalind Franklin University of Medicine and Science Chicago Medical School Founder and Director | Center for Medical Dermatology + Immunology Research Chicago, USA   Raj Chovatiya, MD, PhD, MSCI is Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader.     ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.   Episode supported by and IME Grant from LEO Pharma 📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca✉️[email protected]

🎙️ PART 1:  Real-World Biosimilar Care in HS with Dr. Lauren Lam and Dr. Marni Wiseman HS has officially entered the Skin and Joints chat — and it did not come quietly. In this special Part 1 episode, we welcome back two Skin and Joints Podcast Faculty favourites, dermatologists Dr. Lauren Lam and Dr. Marni Wiseman, for a practical, candid, and refreshingly real-world conversation on hidradenitis suppurativa, biologics, and the evolving role of biosimilars in Canadian care. From delayed diagnosis and cumulative life-course impact to biologic timing, patient expectations, injection burden, access barriers, and the art of asking, “How sick of this are you?” — this episode digs into the clinical realities that do not always fit neatly into trial endpoints. Dr. Lam and Dr. Wiseman share frontline insights on why HS is uniquely challenging, why earlier intervention may change the patient journey, and how biosimilars are reshaping access, dosing conversations, and practical treatment decisions. Expect clinical pearls, a few myth-busting moments, and clinic hot tips you can actually use — from identifying the right referral pathway, to setting realistic goals, minimizing injection burden, considering dose optimization, and translating trial endpoints into real-life wins for patients. Also discussed: tennis dreams, cottage shade, citrate-free formulations, the joy of one injection instead of two, and why HS care is rarely a solo sport. 🎾🌿💉 Learning Objectives After listening to this episode, learners should be able to: Describe why hidradenitis suppurativa is uniquely challenging to manage compared with other chronic inflammatory skin diseases, including the role of delayed diagnosis, comorbidities, surgery, pain, drainage, scarring, and quality-of-life burden. Identify real-world factors that influence biologic initiation in HS, particularly in moderate disease, including patient-reported impact, flare burden, treatment goals, and the importance of earlier intervention when clinically appropriate. Explain the current relevance of adalimumab biosimilars in Canadian HS care, including access, reimbursement, compassionate support, patient counselling, and confidence in biosimilar efficacy and safety. Apply practical counselling strategies for patients starting or switching to biosimilar therapy, including how to discuss expectations, injection burden, pain, formulation differences, and meaningful patient-centred outcomes. Recognize clinic-ready strategies to optimize HS care, including referral tips, patient-centred goal setting, realistic timelines for improvement, combination therapy considerations, and individualized dose optimization in patients with persistent disease activity. #SkinAndJointsPodcast #HidradenitisSuppurativa #HSAwareness #Biosimilars #Adalimumab #Dermatology #RheumDerm #InflammatoryDisease #RealWorldEvidence #PatientCenteredCare #BiologicTherapy #CanadianDermatology #MedicalPodcast #ClinicianEducation #ClinicHotTips #AccessToCare Episode supported by Celltrion Canada.     ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca✉️[email protected]

🎙️The Great Dose Debate: Escalate, De-escalate, or Hold Steady? In this final episode of our AAD 2026 atopic dermatitis post-game poster series, we’re joined by dermatologist Dr. Julien Ringuet from Quebec City for a practical, no-fluff breakdown of the JADE REAL analysis — and what flexible abrocitinib dosing may actually mean when Monday morning clinic rolls around. Because in real life, patients do not always follow a tidy trial algorithm. Symptoms flare, itch keeps people up, adherence shifts, priorities change, and sometimes the “right” dose is less of a fixed destination and more of a GPS recalculating in real time. 🧭 Dr. Ringuet walks us through the clinical “so what” behind dose escalation and de-escalation, explaining why moving from 100 mg to 200 mg — or stepping down from 200 mg to 100 mg — should not automatically be seen as failure, overtreatment, or backpedalling.  Instead, flexible dosing may be part of a thoughtful, shared decision-making strategy that better reflects the messy, dynamic reality of moderate-to-severe atopic dermatitis care. We cover how early reassessment, patient-reported outcomes, itch, sleep, EASI trends, payer flexibility, and treat-to-target thinking all fit into the bigger picture. And yes, we also discuss the real-world art of knowing when to push, when to pause, and when to test the waters with a lower dose. 🌊   ✨ Learning Objectives By the end of this episode, listeners should be able to: Describe how the JADE REAL study design reflects real-world clinical decision-making in moderate-to-severe atopic dermatitis. Explain why dose escalation and de-escalation with abrocitinib may represent intentional treatment optimization rather than treatment failure. Identify practical clinical scenarios where starting at 100 mg versus 200 mg may be appropriate. Discuss how early follow-up, patient-reported outcomes, itch, sleep, and quality-of-life measures can help guide dose adjustment decisions. Recognize key limitations of open-label, real-world evidence when translating study findings into clinical practice. Apply a treat-and-adjust approach to atopic dermatitis management using shared decision-making and individualized treatment goals.   💡 Key Takeaway Flexible dosing is not a loophole — it is real-world dermatology. The win is not finding one perfect pathway for every patient; it is learning how to reassess early, individualize thoughtfully, and adjust with purpose. 🩺 🎧 Tune in for practical pearls, real-world nuance, and Dr. Ringuet’s post-game analysis on what these data may mean for dermatologists managing AD in everyday practice.   #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib  #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor   ABOUT Dr. Julien Ringuet Dermatologist, Quebec City, QC Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ). He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT). Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.   Supported by an IME Grant from PFIZER.         📻www.skinandjoints.ca✉️[email protected]